ResMed, Inspire Medical fall after Lilly's weight-loss drug succeeds in sleep apnea trials

Inspire Medical Systems

17/04/2024 12:52

** Shares of ResMed  RMD.N , Inspire Medical  INSP.N  fall
premarket after Eli Lilly's  LLY.N  weight-loss drug succeeds in
trials testing it in sleep apnea patients
    ** ResMed shares down 6.6% to 172.60, Inspire Medical stock
falls 7.7% to $204.50
    ** Lilly's weight-loss drug helped cut frequency of
irregular breathing in patients with obstructive sleep apnea by
as much as 63% on average across two late-stage trials
    ** LLY shares up 1.2% to $755.72
    ** ResMed and Inspire Medical make medical devices used to
treat sleep apnea, a potentially serious sleep disorder in which
breathing repeatedly stops and starts
    ** As of last close, RMD shares up 7.5% YTD, INSP up ~9%

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))